ClinicalTrials.gg
Active, not recruitingNCT04431726HAVEN 7Updated Oct 1, 2026Results posted

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors

A Phase 3 interventional study of Emicizumab in Severe Hemophilia A, sponsored by Hoffmann-La Roche. Active, not recruiting at 32 sites in 14 countries. Open to participants aged 0 Months to 12 Months. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
0 Months to 12 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing emicizumab in Hemophilia A — 6 open to participants now, 8 under way, 3 of them phase 3. emicizumab · Hemophilia A.

Enrollment
8th of 22
55 · median 27
Started
2021
with 4 others
Phase 3
11 of 22
none open now
Registered
12th of 22
by date
Lead sponsor
10 of 22
Hoffmann-La Roche

Among the 22 studies testing emicizumab in Hemophilia A, this one is the 8th largest by enrollment, is one of 5 that started in 2021, is one of 11 in phase 3, and was the 12th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

6 of the 22 studies testing emicizumab in Hemophilia A are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About emicizumab

emicizumab: first FDA approval 2017 (HEMLIBRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 0 Months to 12 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing emicizumab in Hemophilia A, or all of them as a file.
02

Study summary

This is a Phase IIIb, multicenter, open-label, single-arm study of prophylactic emicizumab in previously untreated and minimally treated patients at study enrollment from birth to ≤12 months of age with severe hemophilia A (intrinsic factor VIII [FVIII] level \<1%) without FVIII inhibitors. The study is designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab administered at 3 milligrams per kilogram of body weight (mg/kg) once every 2 weeks (Q2W) for 52 weeks. After 1 year of treatment, participants will continue to receive emicizumab (1.5 mg/kg once every week [QW], 3 mg/kg Q2W or 6 mg/kg once every 4 weeks [Q4W]) over a 7-year long-term follow-up period under this study frame.

03

Conditions studied

  • Severe Hemophilia A

Browse trials for

Keywords

  • Severe hemophilia A Without Factor VIII Inhibitors
04

Who can participate

Ages eligible
0 Months to 12 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age from birth to ≤12 months at time of
  • Body weight ≥3 kilograms (kg) at time of informed consent. Patients with a lower body weight can be enrolled after they have reached a body weight of 3 kg. Premature babies (gestational age \<38 weeks) may be enrolled as long as they have reached a body weight of 3 kg. For premature babies, the corrected gestational age should be reported.
  • Mandatory receipt of vitamin K prophylaxis according to local standard practice
  • Diagnosis of severe congenital hemophilia A (intrinsic FVIII level \<1%)
  • A negative test for FVIII inhibitor (i.e., \<0.6 Bethesda units [BU]/mL) locally assessed during the 2-week screening period
  • No history of documented FVIII inhibitor (i.e., \<0.6 BU/mL), FVIII drug-elimination half-life \<6 hours, or FVIII recovery \<66%
  • Previously untreated patients or minimally treated patients (i.e., up to 5 days of exposure with hemophilia-related treatments, such as plasma-derived FVIII, recombinant FVIII, fresh frozen plasma, cryoprecipitate, or whole blood products)
  • Documentation of the details of the hemophilia-related treatments received since birth
  • Documentation of the details of the bleeding episodes since birth
  • For patients from birth to \<3 months of age at the time of study entry: no evidence of active intracranial hemorrhage, as confirmed by a negative cranial ultrasound at screening irrespective of delivery mode
  • Adequate hematologic, hepatic, and renal function, as defined in the protocol
  • For parents/caregivers: willingness and ability to comply with the study protocol requirements, scheduled visits, treatment plans, laboratory tests, completion of applicable questionnaires, and other study procedures

Exclusion criteria

Exclusion Criteria:

  • Inherited or acquired bleeding disorder other than severe hemophilia A
  • Use of systemic immunomodulators (e.g., interferon) at enrollment or planned use during the study
  • Receipt of any of the following: Prior use of emicizumab prophylaxis including or commercial emicizumab; An investigational drug to treat or reduce the risk of hemophilic bleeds within 5 drug-elimination half-lives of last drug administration; A non-hemophilia-related investigational drug within the last 30 days or 5 drug-elimination half-lives, whichever is shorter; An investigational drug concurrently
  • Current active severe bleed, such as intracranial hemorrhage
  • Planned surgery (excluding minor procedures, e.g., circumcision, CVAD placement) during the study
  • History of associated with monoclonal antibody therapies or components of the emicizumab injection
  • Patients who are at high risk for thrombotic microangiopathy (TMA) (e.g., have a previous medical or family history of TMA, such as thrombotic thrombocytopenic purpura, atypical hemolytic uremic syndrome) in the investigator's judgment
  • Previous or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis in patients for whom anti-thrombotic treatment is not currently ongoing) or signs of thromboembolic disease
  • Any hereditary or acquired maternal condition that may predispose the patient to thrombotic events (e.g., inherited thrombophilias antiphospholipid syndrome)
  • Other diseases (e.g., certain diseases) that may increase risk of bleeding or thrombosis
  • Known infection with , virus, or virus
  • Serious infection requiring antibiotics or antiviral treatments within 14 days prior to screening
  • Concurrent disease, treatment, abnormality in clinical laboratory tests, vital signs measurements, or physical examination findings that could interfere with the conduct of the study or that would, in the opinion of the investigator or Sponsor, preclude the patient's safe participation in and completion of the study or interpretation of the study results
  • Unwillingness of the parent or caregiver to allow receipt of blood or blood products, or any standard-of-care treatment for a life-threatening condition
  • Any other medical, social, or other condition that may prevent adequate compliance with the study protocol in the opinion of the investigator
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Emicizumab

    Drug: Emicizumab

Interventions

  • Initially, all participants will receive 4 loading doses of 3 milligrams per kilogram (mg/kg) emicizumab subcutaneously (SC) once every week (QW) for 4 weeks followed by the maintenance dosing regimen 3 mg/kg emicizumab SC once every 2 weeks (Q2W) for a total of 52 weeks. Starting from Week 17 of treatment, individual participants may have their dose up-titrated to 3 mg/kg SC QW if they experience suboptimal bleeding control. At the Week 53 clinic visit following consultation with the treating physician, parents/caregivers may elect for their child to continue with the maintenance 3-mg/kg SC Q2W dosing regimen or to switch to the maintenance 1.5-mg/kg SC QW or 6-mg/kg SC once every 4 weeks (Q4W) dosing regimen for the subsequent 7-year long-term follow-up period. During the study, participants will be treated with emicizumab until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria specified in the protocol, whichever occurs first.

    Also known as: Hemlibra, RO5534262, RG6013, ACE910

06

What researchers measure

Primary outcomes

  1. Model-Based Annualized Bleeding Rate for Treated Bleeds

    The number of treated bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

  2. Mean Calculated Annualized Bleeding Rate for Treated Bleeds

    The number of treated bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

  3. Median Calculated Annualized Bleeding Rate for Treated Bleeds

    The number of treated bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

  4. Model-Based Annualized Bleeding Rate for All Bleeds

    The number of all bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

    Time frame: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

  5. Mean Calculated Annualized Bleeding Rate for All Bleeds

    The number of all bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

    Time frame: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

  6. Median Calculated Annualized Bleeding Rate for All Bleeds

    The number of all bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

    Time frame: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

  7. Model-Based Annualized Bleeding Rate for Treated Spontaneous Bleeds

    The number of treated spontaneous bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

  8. Mean Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds

    The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

  9. Median Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds

    The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

  10. Model-Based Annualized Bleeding Rate for Treated Joint Bleeds

    The number of treated joint bleeds over the efficacy period was estimated as an annualized bleed rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

  11. Mean Calculated Annualized Bleeding Rate for Treated Joint Bleeds

    The number of treated joint bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

  12. Median Calculated Annualized Bleeding Rate for Treated Joint Bleeds

    The number of treated joint bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

Secondary outcomes

  1. Hemophilia Joint Health Score (HJHS) Total Score at Specified Timepoints During the Long-Term Follow-Up Period

    Time frame: At Years 4, 5, 6, 7, and 8 of follow-up

  2. Magnetic Resonance Imaging (MRI) Score of Specific Joints at Specified Timepoints During the Long-Term Follow-Up Period

    Time frame: At Years 5 and 8 of follow-up

  3. Incidence and Severity of Adverse Events, With Severity Determined According to World Health Organization (WHO) Toxicity Grading Scale

    Time frame: From first dose of emicizumab until study completion (8 years)

  4. Incidence of Thromboembolic Events

    Time frame: From first dose of emicizumab until study completion (8 years)

  5. Incidence of Thrombotic Microangiopathy

    Time frame: From first dose of emicizumab until study completion (8 years)

  6. Incidence and Severity of of Injection Site Reactions, With Severity Determined According to WHO Toxicity Grading Scale

    Time frame: From first dose of emicizumab until study completion (8 years)

  7. Incidence of Severe Hypersensitivity, Anaphylaxis, and Anaphylactoid Events

    Time frame: From first dose of emicizumab until study completion (8 years)

  8. Incidence of Adverse Events Leading to Study Drug Discontinuation

    Time frame: From first dose of emicizumab until study completion (8 years)

  9. Number of Participants According to Hematology and Serum Chemistry Laboratory Test Result Shifts From Baseline WHO Grade to the Highest WHO Grade Post-Baseline

    Laboratory parameters for hematology and blood chemistry were measured at baseline and over time, and the values were compared with a standard reference range. Values outside the standard reference range were considered laboratory abnormalities and graded according to the World Health Organization (WHO) toxicity grading scale, ranging from lowest (Grade 1) to greatest (Grade 4) deviation from standard in the direction indicated for the abnormality (i.e., below (Low) or above (High) the reference range; 'Not Low' and 'Not High' indicate values within the reference range). Participants were categorized according to their laboratory test result shift from baseline WHO grade to highest WHO grade at any point post-baseline (up to Week 53) for each parameter. 'Missing' indicates that the test result was not available.

    Time frame: Baseline, Weeks 4, 13, 21, 29, 37, 45, and 53

  10. Change From Baseline in Pulse Rate Over Time

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53, and annually during the 7-year follow-up period until study completion (up to 8 years)

  11. Change From Baseline in Respiratory Rate Over Time

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53, and annually during the 7-year follow-up period until study completion (up to 8 years)

  12. Change From Baseline in Body Temperature Over Time

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53, and annually during the 7-year follow-up period until study completion (up to 8 years)

  13. Change From Baseline in Systolic Blood Pressure Over Time

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53, and annually during the 7-year follow-up period until study completion (up to 8 years)

  14. Change From Baseline in Diastolic Blood Pressure Over Time

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53, and annually during the 7-year follow-up period until study completion (up to 8 years)

  15. Plasma Trough Concentrations (Ctrough) of Emicizumab

    Time frame: Predose at Weeks 1, 3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53

  16. Incidence of Anti-Emicizumab Antibodies

    Time frame: Weeks 1, 5, 17, 29, 41, and 53, and thereafter as clinically indicated until study completion (up to 8 years)

  17. Incidence of De Novo Development of Factor VIII Inhibitors

    As per the protocol, after any 3 exposure days to FVIII or a block of FVIII exposure days (e.g., a block is defined as a minimum of two consecutive doses of FVIII) administered for treatment of a bleed, a surgical procedure, or other (e.g., preventative doses before activity), one plasma sample for anti-FVIII antibodies (for centralized analysis) had to be collected 14 days after the final dose of FVIII administered.

    Time frame: As clinically indicated from baseline until study completion (up to 8 years)

07

Results

Posted Jun 14, 2024

Participant flow

Participant flow — Overall Study
MilestoneEmicizumab
Started55
Received at least one dose of study drug55
Completed 52 weeks in the study55
Started the long-term follow-up period55
Completed0
Not completed55
Withdrew: Ongoing in the study55

Outcome measures

PrimaryModel-Based Annualized Bleeding Rate for Treated Bleeds

The number of treated bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Reported as:
Number · Treated bleeds per year
Model-Based Annualized Bleeding Rate for Treated Bleeds
Treated bleeds per yearEmicizumab
Model-Based Annualized Bleeding Rate for Treated Bleeds0.4 (0.30 to 0.63)
PrimaryMean Calculated Annualized Bleeding Rate for Treated Bleeds

The number of treated bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Reported as:
Mean · Treated bleeds per year
Mean Calculated Annualized Bleeding Rate for Treated Bleeds
Treated bleeds per yearEmicizumab
Mean Calculated Annualized Bleeding Rate for Treated Bleeds0.5 (0.00 to 4.59)
PrimaryMedian Calculated Annualized Bleeding Rate for Treated Bleeds

The number of treated bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Reported as:
Median · Treated bleeds per year
Median Calculated Annualized Bleeding Rate for Treated Bleeds
Treated bleeds per yearEmicizumab
Median Calculated Annualized Bleeding Rate for Treated Bleeds0.0 (0.00 to 0.81)
PrimaryModel-Based Annualized Bleeding Rate for All Bleeds

The number of all bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

Time frame:
From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Reported as:
Number · All bleeds per year
Model-Based Annualized Bleeding Rate for All Bleeds
All bleeds per yearEmicizumab
Model-Based Annualized Bleeding Rate for All Bleeds2.0 (1.49 to 2.66)
PrimaryMean Calculated Annualized Bleeding Rate for All Bleeds

The number of all bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

Time frame:
From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Reported as:
Mean · All bleeds per year
Mean Calculated Annualized Bleeding Rate for All Bleeds
All bleeds per yearEmicizumab
Mean Calculated Annualized Bleeding Rate for All Bleeds2.0 (0.24 to 7.22)
PrimaryMedian Calculated Annualized Bleeding Rate for All Bleeds

The number of all bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

Time frame:
From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Reported as:
Median · All bleeds per year
Median Calculated Annualized Bleeding Rate for All Bleeds
All bleeds per yearEmicizumab
Median Calculated Annualized Bleeding Rate for All Bleeds1.0 (0.53 to 2.93)
PrimaryModel-Based Annualized Bleeding Rate for Treated Spontaneous Bleeds

The number of treated spontaneous bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Reported as:
Number · Treated spontaneous bleeds per year
Model-Based Annualized Bleeding Rate for Treated Spontaneous Bleeds
Treated spontaneous bleeds per yearEmicizumab
Model-Based Annualized Bleeding Rate for Treated Spontaneous BleedsNA (NA to NA)
PrimaryMean Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds

The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Reported as:
Mean · Treated spontaneous bleeds per year
Mean Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds
Treated spontaneous bleeds per yearEmicizumab
Mean Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds0.0 (NA to 3.69)
PrimaryMedian Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds

The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Reported as:
Median · Treated spontaneous bleeds per year
Median Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds
Treated spontaneous bleeds per yearEmicizumab
Median Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds0.0 (0.00 to 0.00)
PrimaryModel-Based Annualized Bleeding Rate for Treated Joint Bleeds

The number of treated joint bleeds over the efficacy period was estimated as an annualized bleed rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Reported as:
Number · Treated joint bleeds per year
Model-Based Annualized Bleeding Rate for Treated Joint Bleeds
Treated joint bleeds per yearEmicizumab
Model-Based Annualized Bleeding Rate for Treated Joint Bleeds0.0 (0.0 to 0.1)
PrimaryMean Calculated Annualized Bleeding Rate for Treated Joint Bleeds

The number of treated joint bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Reported as:
Mean · Treated joint bleeds per year
Mean Calculated Annualized Bleeding Rate for Treated Joint Bleeds
Treated joint bleeds per yearEmicizumab
Mean Calculated Annualized Bleeding Rate for Treated Joint Bleeds0.0 (0.00 to 3.75)
PrimaryMedian Calculated Annualized Bleeding Rate for Treated Joint Bleeds

The number of treated joint bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Reported as:
Median · Treated joint bleeds per year
Median Calculated Annualized Bleeding Rate for Treated Joint Bleeds
Treated joint bleeds per yearEmicizumab
Median Calculated Annualized Bleeding Rate for Treated Joint Bleeds0.0 (0.00 to 0.00)
SecondaryHemophilia Joint Health Score (HJHS) Total Score at Specified Timepoints During the Long-Term Follow-Up Period
Time frame:
At Years 4, 5, 6, 7, and 8 of follow-up

Results for this outcome have not been posted.

SecondaryMagnetic Resonance Imaging (MRI) Score of Specific Joints at Specified Timepoints During the Long-Term Follow-Up Period
Time frame:
At Years 5 and 8 of follow-up

Results for this outcome have not been posted.

SecondaryIncidence and Severity of Adverse Events, With Severity Determined According to World Health Organization (WHO) Toxicity Grading Scale
Time frame:
From first dose of emicizumab until study completion (8 years)

Results for this outcome have not been posted.

SecondaryIncidence of Thromboembolic Events
Time frame:
From first dose of emicizumab until study completion (8 years)

Results for this outcome have not been posted.

SecondaryIncidence of Thrombotic Microangiopathy
Time frame:
From first dose of emicizumab until study completion (8 years)

Results for this outcome have not been posted.

SecondaryIncidence and Severity of of Injection Site Reactions, With Severity Determined According to WHO Toxicity Grading Scale
Time frame:
From first dose of emicizumab until study completion (8 years)

Results for this outcome have not been posted.

SecondaryIncidence of Severe Hypersensitivity, Anaphylaxis, and Anaphylactoid Events
Time frame:
From first dose of emicizumab until study completion (8 years)

Results for this outcome have not been posted.

SecondaryIncidence of Adverse Events Leading to Study Drug Discontinuation
Time frame:
From first dose of emicizumab until study completion (8 years)

Results for this outcome have not been posted.

SecondaryNumber of Participants According to Hematology and Serum Chemistry Laboratory Test Result Shifts From Baseline WHO Grade to the Highest WHO Grade Post-Baseline

Laboratory parameters for hematology and blood chemistry were measured at baseline and over time, and the values were compared with a standard reference range. Values outside the standard reference range were considered laboratory abnormalities and graded according to the World Health Organization (WHO) toxicity grading scale, ranging from lowest (Grade 1) to greatest (Grade 4) deviation from standard in the direction indicated for the abnormality (i.e., below (Low) or above (High) the reference range; 'Not Low' and 'Not High' indicate values within the reference range). Participants were categorized according to their laboratory test result shift from baseline WHO grade to highest WHO grade at any point post-baseline (up to Week 53) for each parameter. 'Missing' indicates that the test result was not available.

Time frame:
Baseline, Weeks 4, 13, 21, 29, 37, 45, and 53
Reported as:
Count of participants · Participants
Number of Participants According to Hematology and Serum Chemistry Laboratory Test Result Shifts From Baseline WHO Grade to the Highest WHO Grade Post-Baseline
ParticipantsEmicizumab
Hemoglobin (Low), Not Low to Not Low36
Hemoglobin (Low), Not Low to Grade 15
Hemoglobin (Low), Not Low to Grade 25
Hemoglobin (Low), Grade 1 to Not Low3
Hemoglobin (Low), Grade 1 to Grade 13
Hemoglobin (Low), Grade 1 to Grade 31
Hemoglobin (Low), Grade 1 to Grade 41
Hemoglobin (Low), Grade 2 to Grade 21
Neutrophils, Total, Abs. (Low), Not Low to Not Low8
Neutrophils, Total, Abs. (Low), Not Low to Grade 114
Neutrophils, Total, Abs. (Low), Not Low to Grade 22
Neutrophils, Total, Abs. (Low), Not Low to Grade 33
Neutrophils, Total, Abs. (Low), Not Low to Grade 42
Neutrophils, Total, Abs. (Low), Grade 1 to Not Low4
Neutrophils, Total, Abs. (Low), Grade 1 to Grade 17
Neutrophils, Total, Abs. (Low), Grade 1 to Grade 25
Neutrophils, Total, Abs. (Low), Grade 1 to Grade 31
Neutrophils, Total, Abs. (Low), Grade 2 to Not Low1
Neutrophils, Total, Abs. (Low), Grade 2 to Grade 12
Neutrophils, Total, Abs. (Low), Grade 2 to Grade 21
Neutrophils, Total, Abs. (Low), Grade 2 to Grade 31
Neutrophils, Total, Abs. (Low), Missing to Not Low1
Neutrophils, Total, Abs. (Low), Missing to Grade 11
Neutrophils, Total, Abs. (Low), Missing to Grade 21
Platelets (Low), Not Low to Not Low54
Platelets (Low), Not Low to Grade 21
Alkaline Phosphatase (High), Not High to Not High32
Alkaline Phosphatase (High), Not High to Grade 16
Alkaline Phosphatase (High), Not High to Grade 22
Alkaline Phosphatase (High), Not High to Grade 31
Alkaline Phosphatase (High), Not High to Grade 43
Alkaline Phosphatase (High), Grade 1 to Not High2
Alkaline Phosphatase (High), Grade 1 to Grade 13
Alkaline Phosphatase (High), Grade 1 to Grade 31
Alkaline Phosphatase (High), Grade 2 to Not High1
Alkaline Phosphatase (High), Grade 2 to Grade 11
Alkaline Phosphatase (High), Grade 2 to Grade 21
Alkaline Phosphatase (High), Missing to Not High1
Alkaline Phosphatase (High), Missing to Grade 11
SGPT/ALT (High), Not High to Not High43
SGPT/ALT (High), Not High to Grade 16
SGPT/ALT (High), Not High to Grade 31
SGPT/ALT (High), Not High to Grade 41
SGPT/ALT (High), Grade 1 to Grade 12
SGPT/ALT (High), Grade 1 to Grade 41
SGPT/ALT (High), Missing to Not High1
SGOT/AST (High), Not High to Not High31
SGOT/AST (High), Not High to Grade 111
SGOT/AST (High), Not High to Grade 32
SGOT/AST (High), Grade 1 to Not High2
SGOT/AST (High), Grade 1 to Grade 18
SGOT/AST (High), Grade 1 to Grade 31
Blood Urea Nitrogen (High), Not High to Not High42
Blood Urea Nitrogen (High), Not High to Grade 15
Blood Urea Nitrogen (High), Grade 1 to Grade 12
Blood Urea Nitrogen (High), Missing to Not High4
Calcium (High), Not High to Not High13
Calcium (High), Not High to Grade 118
Calcium (High), Grade 1 to Not High2
Calcium (High), Grade 1 to Grade 117
Calcium (High), Grade 1 to Grade 21
Calcium (High), Grade 2 to Grade 11
Calcium (High), Missing to Not High3
Calcium, Corrected for Albumin (High), Not High to Not High32
Calcium, Corrected for Albumin (High), Not High to Grade 16
Calcium, Corrected for Albumin (High), Grade 1 to Not High6
Calcium, Corrected for Albumin (High), Grade 1 to Grade 15
Calcium, Corrected for Albumin (High), Missing to Not High5
Calcium, Corrected for Albumin (High), Missing to Grade 11
Creatinine (High), Not High to Not High53
Creatinine (High), Not High to Grade 12
Glucose (High), Not High to Not High51
Glucose (High), Not High to Grade 11
Glucose (High), Missing to Not High3
Potassium (High), Not High to Not High40
Potassium (High), Not High to Grade 17
Potassium (High), Grade 1 to Not High4
Potassium (High), Grade 1 to Grade 31
Potassium (High), Missing to Not High1
Potassium (High), Missing to Grade 11
Potassium (High), Missing to Grade 31
Sodium (High), Not High to Not High52
Sodium (High), Grade 1 to Not High1
Sodium (High), Missing to Not High2
Bilirubin (High), Not High to Not High43
Bilirubin (High), Not High to Grade 11
Bilirubin (High), Grade 1 to Not High1
Bilirubin (High), Grade 2 to Not High3
Bilirubin (High), Grade 3 to Not High2
Bilirubin (High), Grade 3 to Grade 11
Bilirubin (High), Grade 4 to Not High1
Bilirubin (High), Grade 4 to Grade 21
Bilirubin (High), Grade 4 to Grade 32
Calcium (Low), Not Low to Not Low50
Calcium (Low), Not Low to Grade 42
Calcium (Low), Missing to Not Low3
Calcium, Corrected for Albumin (Low), Not Low to Not Low47
Calcium, Corrected for Albumin (Low), Not Low to Grade 42
Calcium, Corrected for Albumin (Low), Missing to Not Low6
Glucose (Low), Not Low to Not Low44
Glucose (Low), Not Low to Grade 16
Glucose (Low), Not Low to Grade 21
Glucose (Low), Grade 1 to Not Low1
Glucose (Low), Missing to Not Low3
Magnesium (Low), Not Low to Not Low50
Magnesium (Low), Grade 1 to Not Low2
Magnesium (Low), Missing to Not Low3
Phosphorus (Low), Not Low to Not Low52
Phosphorus (Low), Missing to Not Low3
Postassium (Low), Not Low to Not Low52
Postassium (Low), Missing to Not Low3
Sodium (Low), Not Low to Not Low35
Sodium (Low), Not Low to Grade 113
Sodium (Low), Grade 1 to Not Low1
Sodium (Low), Grade 1 to Grade 14
Sodium (Low), Missing to Not Low1
Sodium (Low), Missing to Grade 11
SecondaryChange From Baseline in Pulse Rate Over Time
Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53, and annually during the 7-year follow-up period until study completion (up to 8 years)

Results for this outcome have not been posted.

SecondaryChange From Baseline in Respiratory Rate Over Time
Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53, and annually during the 7-year follow-up period until study completion (up to 8 years)

Results for this outcome have not been posted.

SecondaryChange From Baseline in Body Temperature Over Time
Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53, and annually during the 7-year follow-up period until study completion (up to 8 years)

Results for this outcome have not been posted.

SecondaryChange From Baseline in Systolic Blood Pressure Over Time
Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53, and annually during the 7-year follow-up period until study completion (up to 8 years)

Results for this outcome have not been posted.

SecondaryChange From Baseline in Diastolic Blood Pressure Over Time
Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53, and annually during the 7-year follow-up period until study completion (up to 8 years)

Results for this outcome have not been posted.

SecondaryPlasma Trough Concentrations (Ctrough) of Emicizumab
Time frame:
Predose at Weeks 1, 3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53
Reported as:
Mean · micrograms per millilitre (μg/mL)
Plasma Trough Concentrations (Ctrough) of Emicizumab
micrograms per millilitre (μg/mL)Emicizumab
Week 1NA ± NA
Week 336.8 ± 9.8
Week 562.0 ± 13.4
Week 762.3 ± 13.5
Week 964.2 ± 14.4
Week 1366.0 ± 12.0
Week 1765.8 ± 13.1
Week 2165.8 ± 13.9
Week 2565.6 ± 15.1
Week 2963.2 ± 14.6
Week 3364.0 ± 21.5
Week 3763.1 ± 15.8
Week 4162.0 ± 17.6
Week 4559.9 ± 16.6
Week 4957.1 ± 14.7
Week 5356.8 ± 15.3
SecondaryIncidence of Anti-Emicizumab Antibodies
Time frame:
Weeks 1, 5, 17, 29, 41, and 53, and thereafter as clinically indicated until study completion (up to 8 years)

Results for this outcome have not been posted.

SecondaryIncidence of De Novo Development of Factor VIII Inhibitors

As per the protocol, after any 3 exposure days to FVIII or a block of FVIII exposure days (e.g., a block is defined as a minimum of two consecutive doses of FVIII) administered for treatment of a bleed, a surgical procedure, or other (e.g., preventative doses before activity), one plasma sample for anti-FVIII antibodies (for centralized analysis) had to be collected 14 days after the final dose of FVIII administered.

Time frame:
As clinically indicated from baseline until study completion (up to 8 years)

Results for this outcome have not been posted.

Adverse events

Collected over From first dose of emicizumab until the primary completion date cutoff (median [range, min-max] observation period: 101.9 [52.6-119.7] weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Emicizumab0/55 (0%)16/55 (29.1%)54/55 (98.2%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventEmicizumab
FallInjury, poisoning and procedural complications4/55
Head injuryInjury, poisoning and procedural complications3/55
BronchiolitisInfections and infestations2/55
BronchitisInfections and infestations2/55
PneumoniaInfections and infestations2/55
TonsillitisInfections and infestations2/55
Mouth haemorrhageGastrointestinal disorders2/55
Tongue haemorrhageGastrointestinal disorders2/55
Ear infectionInfections and infestations1/55
LaryngitisInfections and infestations1/55
Most frequent other events
Showing 10 of 31
Most frequent other events
EventEmicizumab
PyrexiaGeneral disorders26/55
Upper respiratory tract infectionInfections and infestations22/55
NasopharyngitisInfections and infestations18/55
COVID-19Infections and infestations16/55
FallInjury, poisoning and procedural complications16/55
CoughRespiratory, thoracic and mediastinal disorders13/55
DiarrhoeaGastrointestinal disorders12/55
Injection site reactionGeneral disorders11/55
Head injuryInjury, poisoning and procedural complications10/55
RashSkin and subcutaneous tissue disorders10/55

Baseline characteristics

Age, Continuous
Age, Continuous(Months)Emicizumab
Mean5.0 ± 3.9
Sex: Female, Male
Sex: Female, Male(Participants)Emicizumab
Female0
Male55
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Emicizumab
Hispanic or Latino5
Not Hispanic or Latino49
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Emicizumab
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander1
Black or African American1
White48
More than one race0
Unknown or Not Reported2
08

Study locations

32 sites
09

References and documents

Publications

  • Pipe SW, Collins P, Dhalluin C, Kenet G, Schmitt C, Buri M, Jimenez-Yuste V, Peyvandi F, Young G, Oldenburg J, Mancuso ME, Kavakli K, Kiialainen A, Deb S, Niggli M, Chang T, Lehle M, Fijnvandraat K. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial. Blood. 2024 Apr 4;143(14):1355-1364. doi: 10.1182/blood.2023021832. PubMed 38127586 ↗
  • Lopez-Jaime FJ, Benitez O, Diaz Jordan BL, Montano A, Coll J, Quintana Paris L, Gomez-Del Castillo Solano MDC. Expert opinion paper on the treatment of hemophilia a with emicizumab. Hematology. 2023 Dec;28(1):2166334. doi: 10.1080/16078454.2023.2166334. PubMed 36636993 ↗
  • Hart DP. Commentary on "Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach" - Will we ever be able to avoid inhibitor formation in hemophilia A? J Thromb Haemost. 2021 Sep;19(9):2125-2126. doi: 10.1111/jth.15404. No abstract available. PubMed 34435432 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in May 2023, 27 months.

Results were first posted in Jun 2024, 1 year after primary completion.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 27 months is below that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2020
First posted
Jun 16, 2020
StartActual
Feb 4, 2021
Primary completionActual
May 22, 2023
CompletionEst.
May 18, 2030
Results first posted
Jun 14, 2024
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and verification date
1 update, last Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04431726
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 16, 2020
Start date
Feb 4, 2021
Primary completion
May 22, 2023
Completion
May 18, 2030 (estimated)
Results posted
Jun 14, 2024
Last update
Oct 1, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emicizumab

Start the discussion